VTVT
HEALTHCAREvTv Therapeutics Inc - Class A
$31.68-0.12 (-0.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VTVT Today?
No stock-specific AI insight has been generated for VTVT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.00$44.00
$31.68
Fundamentals
Market Cap$125M
P/E Ratio—
EPS$-3.20
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding3.9M
VTVT News
20 articles- vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)The Manila Times·May 8, 2026
- vTv Therapeutics to Participate in Upcoming May Investor ConferencesYahoo Finance·May 7, 2026
- Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?Yahoo Finance·Apr 20, 2026
- Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetYahoo Finance·Apr 2, 2026
- vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin AdvancementsYahoo Finance·Mar 18, 2026
- Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to TradeYahoo Finance·Mar 17, 2026
- vTv Therapeutics to Participate in the 38th Annual ROTH ConferenceYahoo Finance·Mar 16, 2026
- VTv Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 10, 2026
- vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737Yahoo Finance·Mar 4, 2026
- vTv Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 13, 2026
- vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737Yahoo Finance·Feb 2, 2026
- An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?Barchart·Jan 5, 2026
- vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Dec 24, 2025
- We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To GrowYahoo Finance·Dec 19, 2025
- vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of HealthYahoo Finance·Dec 18, 2025
- All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to BuyYahoo Finance·Nov 11, 2025
- VTv Therapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 6, 2025
- vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 6, 2025
- vTv Therapeutics Announces New Appointments to its Scientific Advisory BoardYahoo Finance·Oct 9, 2025
All 20 articles loaded
Price Data
Open$31.71
Previous Close$31.80
Day High$32.67
Day Low$31.68
52 Week High$44.00
52 Week Low$14.00
52-Week Range
$14.00$44.00
$31.68
Fundamentals
Market Cap$125M
P/E Ratio—
EPS$-3.20
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding3.9M
About vTv Therapeutics Inc - Class A
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—